Please assess the completion status of the following clinical trial:

Trial Title: Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Biopsy proven classical Hodgkin lymphoma. Classical Hodgkin lymphoma includes the subtypes of nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted, and classical Hodgkin lymphoma unspecified~* Advanced stage (Stage III or IV) disease~* Measurable disease on cross sectional imaging~* ECOG Performance Status 0-2~* Adequate blood counts and organ function~Exclusion Criteria:~* Pregnant or lactating women~* Laboratory Parameters as outlined in the protocol~* LV ejection fraction lower than normal as assessed by echocardiogram or MUGA scan~* DLCO less than 60% as measured by pulmonary function tests~* Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for over one year~* Current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study~* Life expectancy of less than 12 weeks~* Inability to comply with study procedures~* Inability to give informed consent~* Inadequately controlled hypertension~* Any prior history of hypertensive crisis or hypertensive encephalopathy~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction or unstable angina within 6 months prior to study enrollment~* History of stroke or transient ischemic attack within 6 months prior to study enrollment~* Known CNS involvement of Hodgkin lymphoma~* Significant vascular disease~* Symptomatic peripheral vascular disease~* Evidence of bleeding diatheses or coagulopathy~* Use of daily anticoagulant medications including warfarin, heparins, or aspirin \>325mg daily~* Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days of study enrollment~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment~* Serious, non-healing wound, ulcer, or bone fracture~* Proteinuria at screening~* Known hypersensitivity to any component of bevacizumab~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avastin (Bevacizumab) (Type: OTHER): single-arm, open-label

Based on this trial design, predict the completion outcome and termination type (if applicable).